Trade Cassava Sciences Inc - SAVA CFD

Add to favourite

1.31

9.03%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.13

Long position overnight fee

-0.023679%

Short position overnight fee

0.001457%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	1.44
Open	1.38
1-Year Change	-93.18%
Day's Range	1.29 - 1.39

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Mar 31, 2025	1.44	-0.09	-5.88%	1.53	1.57	1.44
Mar 28, 2025	1.61	-0.05	-3.01%	1.66	1.72	1.57
Mar 27, 2025	1.65	0.01	0.61%	1.64	1.68	1.58
Mar 26, 2025	1.68	-0.15	-8.20%	1.83	1.94	1.68
Mar 25, 2025	1.83	-0.30	-14.08%	2.13	2.26	1.74
Mar 24, 2025	2.73	-0.05	-1.80%	2.78	2.85	2.72
Mar 21, 2025	2.77	0.14	5.32%	2.63	2.83	2.63
Mar 20, 2025	2.70	0.07	2.66%	2.63	2.75	2.63
Mar 19, 2025	2.65	-0.09	-3.28%	2.74	2.77	2.59
Mar 18, 2025	2.72	0.06	2.26%	2.66	2.99	2.66
Mar 17, 2025	2.71	0.02	0.74%	2.69	2.74	2.69
Mar 14, 2025	2.72	0.19	7.51%	2.53	2.73	2.53
Mar 13, 2025	2.54	-0.10	-3.79%	2.64	2.74	2.54
Mar 12, 2025	2.66	0.16	6.40%	2.50	2.70	2.50
Mar 11, 2025	2.51	-0.09	-3.46%	2.60	2.60	2.43
Mar 10, 2025	2.60	-0.09	-3.35%	2.69	2.76	2.59
Mar 7, 2025	2.74	0.02	0.74%	2.72	2.83	2.68
Mar 6, 2025	2.74	0.12	4.58%	2.62	2.78	2.62
Mar 5, 2025	2.70	0.07	2.66%	2.63	2.71	2.52
Mar 4, 2025	2.60	0.22	9.24%	2.38	2.61	2.30

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cassava Sciences Inc. Company profile

Cassava Science Inc is a clinical-stage biopharmaceutical company that specialises in detecting and treating Alzheimer’s disease, an incurable progressive neurologic disorder, which is . The company is listed on the Nasdaq under the ticker SAVA.

According to Cassava, over five million people in the US have Alzheimer’s. The company focuses on research and development to find new approaches for its treatment and diagnosis.

Cassava is developing Simufilam for the proposed treatment of Alzheimer's. According to the company, Simufilam is a proprietary oral drug candidate, developed in-house with academic collaborators. Simufilam, or PTI-125, is the company’s lead therapeutic product candidate. It’s currently (17 March) undergoing Phase 3 clinical studies.

SavaDx is the company’s investigational diagnostic for Alzheimer’s. According to the company, SavaDx is being developed to detect the disease with a simple blood test. However, SavaDx is still an early-stage product candidate and a lower priority than Simufilam, Cassava said.

Cassava was incorporated in 1998. It’s based in Austin, Texas, US. Remi Barbier has served as president, CEO and chairman of the board of directors since the company’s inception. Nadav Friedmann is the company’s chief medical officer. James Kupiec is the chief clinical development officer.

Industry:

Bio Therapeutic Drugs

6801 N Capital Of Texas Highway
Building 1; Suite 300
AUSTIN
TEXAS 78731
US